product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Human B7-H3 Antibody
catalog :
AF1027
quantity :
100 ug (also 25 ug)
price :
499 USD
clonality :
polyclonal
host :
domestic goat
conjugate :
nonconjugated
reactivity :
human, mouse, bovine
application :
western blot, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section
more info or order :
R&D Systems product webpage
citations: 30
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry; human; 1:1000; fig 4a
Lavoie R, Gargollo P, Ahmed M, Kim Y, Baer E, Phelps D, et al. Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. Cancers (Basel). 2021;13: pubmed publisher
Seo Y, Lee J, Ryu H, Kim E, Kim S, Jeong J, et al. Lateral interactions between CD276 and CD147 are essential for stemness in breast cancer: a novel insight from proximal proteome analysis. Sci Rep. 2023;13:14242 pubmed publisher
Haydar D, Iba xf1 ez Vega J, Crawford J, Chou C, Guy C, Meehl M, et al. CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity. Res Sq. 2023;: pubmed publisher
Hashimoto N, Suzuki T, Ishizawa K, Nobusawa S, Yokoo H, Nishikawa R, et al. A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment. Brain Tumor Pathol. 2023;40:163-175 pubmed publisher
Petterson S, S xf8 rensen M, Burton M, Thomassen M, Kruse T, Michaelsen S, et al. Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas. Brain Pathol. 2023;33:e13111 pubmed publisher
Shi X, Day A, Bergom H, Tape S, Baca S, Sychev Z, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol. 2022;6:80 pubmed publisher
Joung J, Kirchgatterer P, Singh A, Cho J, Nety S, Larson R, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun. 2022;13:1606 pubmed publisher
Zhang M, Zhang H, Fu M, Zhang J, Zhang C, Lv Y, et al. The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas. Front Cell Dev Biol. 2021;9:670145 pubmed publisher
Wang R, Sun L, Xia S, Wu H, Ma Y, Zhan S, et al. B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway. Cell Death Dis. 2021;12:453 pubmed publisher
Lee M, Lu Z, Shoemaker C, Tremblay J, St Croix B, Seaman S, et al. Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody. J Control Release. 2021;334:106-113 pubmed publisher
Michelakos T, Kontos F, Barakat O, Maggs L, Schwab J, Ferrone C, et al. B7-H3 targeted antibody-based immunotherapy of malignant diseases. Expert Opin Biol Ther. 2021;21:587-602 pubmed publisher
Cheng R, Wang B, Cai X, Chen Z, Du Q, Zhou L, et al. CD276 Promotes Vasculogenic Mimicry Formation in Hepatocellular Carcinoma via the PI3K/AKT/MMPs Pathway. Onco Targets Ther. 2020;13:11485-11498 pubmed publisher
Ma Y, Zhan S, Lu H, Wang R, Xu Y, Zhang G, et al. B7-H3 regulates KIF15-activated ERK1/2 pathway and contributes to radioresistance in colorectal cancer. Cell Death Dis. 2020;11:824 pubmed publisher
Sievil xe4 inen M, Wirsing A, Hyyti xe4 inen A, Almahmoudi R, Rodrigues P, Bjerkli I, et al. Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator. Head Neck Pathol. 2021;15:469-478 pubmed publisher
Ganesan B, Parameswaran S, Sharma A, Krishnakumar S. Clinical relevance of B7H3 expression in retinoblastoma. Sci Rep. 2020;10:10185 pubmed publisher
Bachawal S, Bean G, Krings G, Wilson K. Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression. NPJ Breast Cancer. 2020;6:14 pubmed publisher
Lu H, Shi T, Wang M, Li X, Gu Y, Zhang X, et al. B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells. Oncoimmunology. 2020;9:1748991 pubmed publisher
Theruvath J, Sotillo E, Mount C, Graef C, Delaidelli A, Heitzeneder S, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med. 2020;26:712-719 pubmed publisher
Ma Y, Wang R, Lu H, Li X, Zhang G, Fu F, et al. B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A. J Cancer. 2020;11:2158-2170 pubmed publisher
Zhan S, Liu Z, Zhang M, Guo T, Quan Q, Huang L, et al. Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas. Front Oncol. 2019;9:1466 pubmed publisher
Wang R, Ma Y, Zhan S, Zhang G, Cao L, Zhang X, et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression. Cell Death Dis. 2020;11:55 pubmed publisher
Nehama D, Di Ianni N, Musio S, Du H, Patanè M, Pollo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine. 2019;47:33-43 pubmed publisher
Shi T, Ma Y, Cao L, Zhan S, Xu Y, Fu F, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10:308 pubmed publisher
Zhang J, Wang J, Marzese D, Wang X, Yang Z, Li C, et al. B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma. Lab Invest. 2019;: pubmed publisher
Cai L, Michelakos T, Deshpande V, Arora K, Yamada T, Ting D, et al. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clin Cancer Res. 2019;25:2644-2655 pubmed publisher
Majzner R, Theruvath J, Nellan A, Heitzeneder S, Cui Y, Mount C, et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res. 2019;25:2560-2574 pubmed publisher
Wilson K, Bachawal S, Abou Elkacem L, Jensen K, Machtaler S, Tian L, et al. Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer using a B7-H3-targeted ICG Contrast Agent. Theranostics. 2017;7:1463-1476 pubmed publisher
Quandt D, Fiedler E, Muller A, Marsch W, Seliger B. High constitutive B7-H3 expression on human keratinocytes supports T cell immunity. J Dermatol Sci. 2017;87:82-85 pubmed publisher
Li Y, Guo G, Song J, Cai Z, Yang J, Chen Z, et al. B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway. J Cancer. 2017;8:816-824 pubmed publisher
Yoon B, Chung Y, Yoo S, Kawara K, Kim J, Yoo I, et al. Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid Arthritis. J Biol Chem. 2016;291:4048-57 pubmed publisher
product information
brand :
R&D Systems
master code :
AF1027
SKU :
AF1027
product name :
Human B7-H3 Antibody
unit size :
100 ug (also 25 ug)
seo description :
The Human B7-H3 Antibody from R&D Systems is a goat polyclonal antibody to B7-H3/CD276. This antibody reacts with bovine,human,mouse,transgenic mouse. The Human B7-H3 Antibody has been validated for the following applications: Immunohistochemistry,Western Blot,Flow Cytometry,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry,Simple Western,CyTOF-ready,Knockout Validated.
target :
B7-H3
category :
Primary Antibodies
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.
clonality :
Polyclonal
concentration :
LYOPH
conjugate :
Unconjugated
dilution :
Western Blot 1 ug/mL, Simple Western 10 ug/mL, Flow Cytometry 0.25 ug/10^6 cells, Immunohistochemistry 5-15 ug/mL, CyTOF-ready, Knockout Validated
host :
Goat
immunogen :
Mouse myeloma cell line NS0-derived recombinant human B7-H3, Leu29-Pro245, Accession # NP_079516
isotype :
IgG
purity :
Antigen Affinity-purified
species :
Bovine,Human,Mouse
specificity :
Detects human B7-H3 in direct ELISAs and Western blots.
gene symbol :
CD276
Antibody validation :
Knockout/Knockdown
top caption :
Detection of Human B7-H3 antibody by Western Blot.
accessionNumbers :
NP_079516
applications :
Simple Western,CyTOF-ready,Knockout Validated,Flow Cytometry,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry
USD :
499 USD
alt names :
B7H3, B7H34Ig-B7-H3, B7-H3B7 homolog 3, CD276, CD276 antigen, CD276 molecule, Costimulatory molecule
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.